Abstract:Abstract Molecular diagnosis has become highly significant for patient management. Facing new challenges to generate more comprehensive data in reduced time and cost, we tested Nanopore (ONT) adaptive sampling to analyze a gene panel for germline predisposition to cancer. We tested 30 clinical germline samples carrying known alterations on BRCA1, BRCA2, PALB2 and MLH1 genes to detect large scale rearrangements (LSR) and single nucleotide variants (SNV). We used adaptive sampling to enrich the full sequence (from promoters to 3’UTR) of 152 cancer predisposition genes on ONT R10.4.1 MinION flowcells and the Q20 chemistry. The analysis was performed using the long-read bioinformatics pipeline developed by SeqOne Genomics. We observed a mean enrichment of 7.85 (3.91-9.85) and a mean coverage on target genes of 14.73X (4.71-35). In our cohort, 11 samples had LSR that were all detected with ONT sequencing. In addition to perfectly detect the locus of the LSR (starts and stops always in intronic regions), we discovered that a known MLPA amplification of exon 13 in the BRCA1 gene was in fact an amplification of both exons 12 and 13. This 2-exon duplication was also confirmed on a patient’s relative, originally diagnosed with an exon 13 duplication as well. Another LSR was a total deletion of the BRCA1 gene. ONT sequencing highlighted this complete deletion of BRCA1 was the consequence of a large deletion of almost 140 kbp carrying 5 different genes (BRCA1, IFI35, NBR2, RND2, and VAT1). ONT sequencing was also able to detect all class-5 SNVs (point mutations and small indel) present in 16 patient samples at low coverage (between 6 and 27X). We faced bioinformatics detection issues for 3 mutations located in homopolymer regions using standard pipelines. These were all confirmed correctly when visualizing the raw data. As we analyzed complete genes and more genes than with short read sequencing, we detected novel unknown variants. To check the reliability of those novel variant by ONT, we wondered whether we could confirm results obtained at a low coverage (10X) with average quality (Phread score >/= 15). For that we randomly selected 8 new variants we analyzed by Sanger sequencing, and all of these were confirmed, suggesting that variants detected with ONT, even at a 10X coverage and a Phread score higher than 15, could be considered as real variants. In conclusion, we showed that ONT adaptive sampling sequencing is suitable for the analysis of germline alterations. It improves the characterization of LSR and is able to detect SNV even at low coverage. Nevertheless, an improvement of bioinformatics detection of variants located in homopolymer regions should be considered. A larger comparison study between ONT adaptive sampling and short read sequencings should be performed on hundreds of samples to adapt international guidelines to third generation sequencing for germline diagnosis. Citation Format: Sandy Chevrier, Corentin Richard, Marie Mille, Denis Bertrand, Michael Blum, Nicolas Philippe, Romain Boidot. Nanopore adaptive sampling detects nucleotide variants and improves large scale rearrangement characterization for diagnosis of cancer predisposition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2936.

BRCA Testing by Single-Molecule Molecular Inversion Probes

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly

Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples

A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes

Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads

Automated genotyping of biobank samples by multiplex amplification of insertion/deletion polymorphisms

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing

Clinical-grade whole genome sequencing-based haplarithmisis enables all forms of preimplantation genetic testing

Abstract 2936: Nanopore adaptive sampling detects nucleotide variants and improves large scale rearrangement characterization for diagnosis of cancer predisposition

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing

Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies

Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service

A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis

External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

Abstract 2279: Cas9 based targeted nanopore sequencing helps identify structural variants in breast cancer genes

Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling

Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany

Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing

A novel high-throughput assay using mixed genomic DNA for fast screening germline pathogenic variants in breast cancer susceptibility genes